Participants 55 72 4
autistic disorder
Participants 308 360 5
pediatric subjects receiving aripiprazole treatment.
Participants 550 608 7
pediatric subjects with autistic disorder, aged 6-17 years
Participants 913 1004 5
316 randomized subjects, 259 (82.0%) were antipsychotic na√Øve (AN) and 57 (18.0%) had a PA
Participants 2092 2146 4
 younger subjects with a higher baseline weight z-scor
Participants 2397 2444 6
 children and adolescents with autistic disorde
